News Release

Former NASDAQ executive, Meyer ‘Sandy’ Frucher, appointed to Eikonoklastes Therapeutics Board of Directors

Biopharmaceutical company

Business Announcement


Cincinnati, OH – June 29, 2022 – Eikonoklastes Therapeutics, Inc., a private biotech company, today announced the appointment of Meyer (Sandy) Frucher to its Board of Directors.

Frucher is a seasoned executive and board director who brings a wealth of experience in the financial and public sectors. Recently retired, Sandy was most previously Vice-Chairman of NASDAQ, where he was responsible for global exchange relationships and served as a senior advisor to NASDAQ’s senior management team on a broad range of industry and regulatory issues. He was also the Chief Ambassador on Sustainability issues around the globe for NASDAQ. Frucher joined the exchange in 2008 after NASDAQ OMX completed its acquisition of The Philadelphia Stock Exchange, where he served as Chairman and CEO, for $700 million.  

“Eikonoklastes is building a uniquely differentiated approach in regards to both corporate strategy and scientific innovation,” Frucher said. “I look forward to offering my breadth of leadership experience to serve the Eikonoklastes management team and maximize impact for patients and other stakeholders.”

“Sandy has made a tremendous impact and delivered impressive results everywhere he has gone,” said Bruce Halpryn, Ph.D., CEO of Eikonoklastes Therapeutics. “We are excited for Sandy’s valuable contributions and skillset to complement the management team’s sustained record of success as we develop multiple potentially life-saving medicines to treat devastating diseases.”

Frucher is also the founding Chairman and Trustee Emeritus of the Board of the Massachusetts Museum of Contemporary Art, an institution responsible for developing the largest center for contemporary visual and performing arts in the United States. He also sits on the Board of the Saratoga Performing Arts Center located in Saratoga Springs, NY.


About Eikonoklastes Therapeutics, Inc.

Eikonoklastes Therapeutics, Inc. is a biotechnology company rapidly developing disruptive treatments for today’s most challenging diseases. The company was founded in 2019 by iconoclasts building a new kind of biotech, keenly identifying breakthrough technologies in areas of unmet clinical need, and then efficiently advancing these medicines towards major value inflection points.


About CincyTech

Founded in 2006, CincyTech works to transform undeniably better ideas into high-performing life science and digital companies in Southwest Ohio. Our team provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups, and catalyzes investment from individuals and institutions into regional companies. Eikonoklastes Therapeutics is a CincyTech portfolio company.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.